Myelodysplastic syndromes
In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and have problems making new blood cells. Many of the blood cells formed by these bone marrow cells are defective. Defective cells often die earlier than normal cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in MDS is a shortage of red blood cells (anemia).
Types of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are classified using the World Health Organization (WHO) classification system, which was most recently updated in 2016. It divides MDS into types based mainly on how the cells in the bone marrow look under the microscope, as well as some other factors:
How many early forms of cell types in the bone marrow (red blood cells, white blood cells, or platelets) show dysplasia (look abnormal under the microscope). 
MDS, unclassifiable (MDS-U)
q Because small differences in the way the cells look can change the diagnosis, doctors may sometimes disagree on a patient's exact type of MDS.
MDS with multilineage dysplasia (MDS-MLD)
In MDS-MLD: Dysplasia is seen in at least 10% of the early cells of 2 or 3 cell types (red blood cells, white blood cells, and/or megakaryocytes [the cells that make platelets]) in the bone marrow. There is a normal number (less than 5%) of very early cells called blasts in the bone marrow, and blasts are rare (or absent) in the blood. q This is the most common type of MDS. In the past, it was referred to as refractory cytopenia with multilineage dysplasia (RCMD).
MDS with single lineage dysplasia (MDS-SLD)
In MDS-SLD: This was referred to as refractory cytopenia with unilineage dysplasia (RCUD) in the previous classification system. It includes refractory anemia (RA), refractory neutropenia (RN), and refractory thrombocytopenia (RT), depending on which cell type is affected.
MDS with ring sideroblasts (MDS-RS)
In this type of MDS, many of the early red blood cells are ring sideroblasts. For this diagnosis, at least 15% of the early red blood cells must be ring sideroblasts (or at least 5% if the cells also have a mutation in the SF3B1 gene).
This condition is further divided into 2 types, based on how many of the cell types in the bone marrow are affected by dysplasia:
MDS-RS with single lineage dysplasia (MDS-RS-SLD): dysplasia in only one cell type q

MDS-RS with multilineage dysplasia (MDS-RS-MLD): dysplasia in more than one cell type q
This type of MDS is not common. It rarely turns into AML 2 , and the outcome for people with this type is generally better than for some other types of MDS. This was previously referred to as refractory anemia with ring sideroblasts (RARS).
MDS with excess blasts (MDS-EB) ____________________________________________________________________________________
In this type of MDS, there are more blasts than normal in the bone marrow and/or blood. The person also has low numbers of at least one type of blood cell. There may or may not be severe dysplasia in the bone marrow.
This condition is further divided into 2 types, based on how many of the cells in the bone marrow or blood are blasts: MDS-EB1: blasts make up 5% to 9% of the cells in the bone marrow, or 2% to 4% of the cells in the blood q MDS-EB2: blasts make up 10% to 19% of the cells in the bone marrow, or 5% to 19% of the cells in the blood q This type accounts for about 1 in 4 cases of MDS. It is one of the types most likely to turn into AML 3 , with the risk being higher for MDS-EB2 than for MDS-EB1. This was previously referred to as refractory anemia with excess blasts (RAEB).
MDS with isolated del(5q)
In this type of MDS, the chromosomes of the bone marrow cells are missing part of chromosome number 5. (There may also be one other chromosome abnormality, as long as it isn't a loss of part or all of chromosome 7.) The person also has low numbers of 1 or 2 types of blood cells (usually red blood cells), and there is dysplasia in at least 1 cell type in the bone marrow.
This type of MDS is not common. It occurs most often in older women. For reasons that aren't clear, patients with this type of MDS tend to have a good prognosis (outlook). They often live a long time and rarely go on to develop AML 4 .
MDS, unclassifiable (MDS-U)
This type of MDS is uncommon. For MDS-U, the findings in the blood and bone marrow don't fit any other type of MDS. For example, the numbers of any one of the cell types may be low in the blood, but less than 10% of that type of cell looks abnormal in the bone marrow. Or the cells in the bone marrow have at least one certain chromosome abnormality that is only seen in MDS or leukemia. This type is rare, so it has not been studied well enough to predict prognosis (outlook).
Clinical classification of MDS Syndrome Research?
Research into the causes, diagnosis, and treatment of myelodysplastic syndromes (MDS) is being done at many cancer research centers around the world.
Genetics and biology of MDS
Scientists are making progress in understanding how changes in the DNA (genes) inside normal bone marrow cells can cause them to develop into myelodysplastic cells. It's also clear that not all cases of MDS have the same gene changes. An improved understanding of this is helping to better classify different types of MDS 1 and to determine a person's likely prognosis (outlook). It might also help determine which patients might benefit most from different types of treatment.
Scientists are also learning how bone marrow stromal cells influence MDS cells. Stromal cells in the bone marrow do not develop into blood cells. Instead, they help support, nourish, and regulate the blood-forming cells. Some studies suggest that although the stromal cells in MDS patients are not cancerous, they are not normal either, and seem to have a role in causing MDS. Scientists have identified some of the chemical signals that are exchanged between stromal cells and MDS cells.
As more information from this research unfolds, it may be used to help develop new drugs or other types of treatment.
Chemotherapy
Studies are being done to find new drugs and drug combinations that might work better, as well as having less serious side effects.
Drugs called hypomethylating agents 2 , such as azacitidine (Vidaza) and decitabine (Dacogen), are currently some of the most effective drugs in treating MDS. But they're not helpful for everyone, and they eventually stop working for most people. Guadecitabine is a newer drug that is related to decitabine, but it stays inside cells longer, so in theory it might work better. It has helped some people in early studies, and is now being tested in a larger study.
Researchers are also testing oral (by mouth) forms of azacitidine and decitabine, which might be easier for patients to take.
Research is also under way to see if there are some patients who might benefit from ____________________________________________________________________________________ more intensive chemotherapy.
Immune suppression
In some people with MDS, the immune system seems to interfere with normal blood cell production. Some medicines 3 , such as ATG and cyclosporine, are already being used to treat some people with MDS. Researchers are now looking at other ways to suppress the immune system in people with MDS to see if this might be helpful.
Targeted therapy
Targeted therapy drugs work differently from standard chemotherapy drugs. They affect specific parts of cancer cells that make them different from normal, healthy cells. Targeted drugs might work in some cases where chemotherapy doesn't, and they tend to have different (and sometimes less severe) side effects. Targeted drugs are now part of the treatment for many types of cancer, and they are being studied for use in MDS as well.
For example, luspatercept is a new drug that blocks cellular proteins that are part of the TGF-beta superfamily. These proteins slow down red blood cell production. In early studies, this drug has shown a lot of promise in raising red blood cell levels in people with lower-risk forms of MDS. Further studies of this and similar drugs are under way.
Rigosertib is a new drug that targets several different proteins that normally help cancer cells grow. This drug has been shown to help some people with high-risk MDS in early studies, and is now being studied for use by itself and along with azacitidine.
Other new targeted drugs now being studied for use in MDS include:
Imetelstat, a telomerase inhibitor 
Stem cell transplant Written by
American Cancer Society cancer.org | 1.800.227.2345 ____________________________________________________________________________________ The American Cancer Society medical and editorial content team (https://www.cancer.org/content/cancer/en/cancer/acs-medical-content-and-newsstaff.html) Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy (https://www.cancer.org/content/cancer/en/about-us/policies/content-usage.html).
cancer.org | 1.800.227.2345
